362 related articles for article (PubMed ID: 25340931)
1. Novel targeted therapies for eosinophil-associated diseases and allergy.
Radonjic-Hoesli S; Valent P; Klion AD; Wechsler ME; Simon HU
Annu Rev Pharmacol Toxicol; 2015; 55():633-56. PubMed ID: 25340931
[TBL] [Abstract][Full Text] [Related]
2. Eosinophils as a pharmacological target for the treatment of allergic diseases.
Landolina NA; Levi-Schaffer F
Curr Opin Pharmacol; 2014 Aug; 17():71-80. PubMed ID: 25128782
[TBL] [Abstract][Full Text] [Related]
3. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
4. Anti-allergic therapies: effects on eosinophil progenitors.
Baatjes AJ; Sehmi R; Saito H; Cyr MM; Dorman SC; Inman MD; O'Byrne PM; Denburg JA
Pharmacol Ther; 2002 Jul; 95(1):63-72. PubMed ID: 12163128
[TBL] [Abstract][Full Text] [Related]
5. Targeting eosinophils in allergy, inflammation and beyond.
Fulkerson PC; Rothenberg ME
Nat Rev Drug Discov; 2013 Feb; 12(2):117-29. PubMed ID: 23334207
[TBL] [Abstract][Full Text] [Related]
6. Biological Modulators in Eosinophilic Diseases.
Sriaroon P; Ballow M
Clin Rev Allergy Immunol; 2016 Apr; 50(2):252-72. PubMed ID: 25129490
[TBL] [Abstract][Full Text] [Related]
7. CD28 and secretory immunoglobulin A-dependent activation of eosinophils: inhibition of mediator release by the anti-allergic drug, suplatast tosilate.
Woerly G; Decot V; Loiseau S; Loyens M; Chihara J; Ono N; Capron M
Clin Exp Allergy; 2004 Sep; 34(9):1379-87. PubMed ID: 15347370
[TBL] [Abstract][Full Text] [Related]
8. The activity of medicinal plants and secondary metabolites on eosinophilic inflammation.
Rogerio AP; Sá-Nunes A; Faccioli LH
Pharmacol Res; 2010 Oct; 62(4):298-307. PubMed ID: 20450976
[TBL] [Abstract][Full Text] [Related]
9. Indomethacin inhibits eosinophil migration to prostaglandin D2 : therapeutic potential of CRTH2 desensitization for eosinophilic pustular folliculitis.
Kataoka N; Satoh T; Hirai A; Saeki K; Yokozeki H
Immunology; 2013 Sep; 140(1):78-86. PubMed ID: 23582181
[TBL] [Abstract][Full Text] [Related]
10. The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders.
Legrand F; Tomasevic N; Simakova O; Lee CC; Wang Z; Raffeld M; Makiya MA; Palath V; Leung J; Baer M; Yarranton G; Maric I; Bebbington C; Klion AD
J Allergy Clin Immunol; 2014 May; 133(5):1439-47, 1447.e1-8. PubMed ID: 24530099
[TBL] [Abstract][Full Text] [Related]
11. Induction of eosinophil apoptosis by the cyclin-dependent kinase inhibitor AT7519 promotes the resolution of eosinophil-dominant allergic inflammation.
Alessandri AL; Duffin R; Leitch AE; Lucas CD; Sheldrake TA; Dorward DA; Hirani N; Pinho V; de Sousa LP; Teixeira MM; Lyons JF; Haslett C; Rossi AG
PLoS One; 2011; 6(9):e25683. PubMed ID: 21984938
[TBL] [Abstract][Full Text] [Related]
12. Mast cell and eosinophil surface receptors as targets for anti-allergic therapy.
Gangwar RS; Landolina N; Arpinati L; Levi-Schaffer F
Pharmacol Ther; 2017 Feb; 170():37-63. PubMed ID: 27773785
[No Abstract] [Full Text] [Related]
13. Anti-interleukin-5 antibody therapy in asthma and allergies.
Corren J
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):565-70. PubMed ID: 21971335
[TBL] [Abstract][Full Text] [Related]
14. Eosinophil progenitors in allergy and asthma - do they matter?
Rådinger M; Lötvall J
Pharmacol Ther; 2009 Feb; 121(2):174-84. PubMed ID: 19059433
[TBL] [Abstract][Full Text] [Related]
15. Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis.
Aceves SS; Ackerman SJ
Immunol Allergy Clin North Am; 2009 Feb; 29(1):197-211, xiii-xiv. PubMed ID: 19141355
[TBL] [Abstract][Full Text] [Related]
16. Changing roles of eosinophils in health and disease.
Furuta GT; Atkins FD; Lee NA; Lee JJ
Ann Allergy Asthma Immunol; 2014 Jul; 113(1):3-8. PubMed ID: 24795292
[TBL] [Abstract][Full Text] [Related]
17. Eotaxin and eosinophil recruitment: implications for human disease.
Rankin SM; Conroy DM; Williams TJ
Mol Med Today; 2000 Jan; 6(1):20-7. PubMed ID: 10637571
[TBL] [Abstract][Full Text] [Related]
18. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Harish A; Schwartz SA
Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
[TBL] [Abstract][Full Text] [Related]
19. Eosinophils in Health and Disease: A State-of-the-Art Review.
Wechsler ME; Munitz A; Ackerman SJ; Drake MG; Jackson DJ; Wardlaw AJ; Dougan SK; Berdnikovs S; Schleich F; Matucci A; Chanez P; Prazma CM; Howarth P; Weller PF; Merkel PA
Mayo Clin Proc; 2021 Oct; 96(10):2694-2707. PubMed ID: 34538424
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptor 2 augments eosinophil responsiveness and aggravates allergen-induced pulmonary inflammation in mice.
Frei RB; Luschnig P; Parzmair GP; Peinhaupt M; Schranz S; Fauland A; Wheelock CE; Heinemann A; Sturm EM
Allergy; 2016 Jul; 71(7):944-56. PubMed ID: 26850094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
